10 combination product development experts

Combination product titles at AstraZeneca, Merck, Takeda, Eli Lilly and Company, Teva Pharmaceuticals, AbbVie, Kiniksa Pharmaceuticals, Viatris and Bayer belong to these combination product development experts, two of whom also worked at West Pharmaceutical Services. Their pen injector, injectables and respiratory work suits choosing a delivery device, splitting device and drug product tasks, or reaching submission and transfer to production.

10 professionals9 companiesData retrieved October 4, 2026

Professionals to explore

  1. Chris Mitchener

    LinkedIn

    Experience: Exec. Director Device & Combination Product Development · Eli Lilly and Company

    $606 per 30-minute call

    Chris Mitchener has been Exec. Director Device & Combination Product Development at Eli Lilly and Company since March 2023, with leadership and program and platform management responsibility for Device & Biotech Product R&D. Other Lilly titles include Sr. Director Device & Combination Product Development (2015-2023), Sr. Director Device Manufacturing (2014-2015) and Assoc. Director Device & Combination Product Development (2006-2011), a fit for questions on device platforms.

    Is this you? Claim your profile and get paid for calls.

  2. Chris Smith

    LinkedIn

    Experience: Director, Combination Product Devices · Teva Pharmaceuticals

    $471 per 30-minute call

    As Director, Combination Product Devices at Teva Pharmaceuticals since 2020, Chris Smith is head of the pen injector technology cluster, managing engineers, technicians and project managers and delivering pen-injector combination projects through development, verification, validation, submission and transfer to production. Smith was Head of Engineering, Steriles Device Team at Teva (2018-2019) and Design Authority at Sanofi (2006-2010).

    Is this you? Claim your profile and get paid for calls.

  3. Jeffrey C. Givand

    LinkedIn

    Experience: Former Director Of Device and Combination Product Development · Merck

    $539 per 30-minute call

    At Merck, Jeffrey C. Givand was most recently Executive Director (2021-2026), after Director Of Device and Combination Product Development (2013-2021) and Associate Director, Product Development (2009-2013). Givand describes over 26 years in both pharmaceutical drug product and process development and drug-device combination product development, which suits questions on keeping drug product and device work in step.

    Is this you? Claim your profile and get paid for calls.

  4. Joyce Y Zhao, PhD

    LinkedIn

    Experience: Director, Combination Product Medical Device · Takeda

    $539 per 30-minute call

    Joyce Y Zhao, PhD has been Director, Combination Product Medical Device at Takeda since April 2023, after Associate Director, Combination Product Device Development there (2019-2023). Zhao held the same associate director title at Dr. Reddy's Laboratories (2016-2018) and was Staff Engineer, Technical Lead at BD (2010-2016), and names risk management systems (ISO13485, 21CFR820.30, MDR) and regulatory submissions to FDA, EMA and PMDA as areas of expertise.

    Is this you? Claim your profile and get paid for calls.

  5. Julie Ann Jones

    LinkedIn

    Experience: Director, Device Program Lead (Drug Device Combination Products) · Viatris

    $471 per 30-minute call

    Julie Ann Jones leads program management teams developing respiratory and injectable products as Director, Device Program Lead (Drug Device Combination Products) at Viatris since August 2022, building plans in line with regulatory strategies. Jones was also Senior Manager - Lead for Combination Product Development Projects at Teva Pharmaceuticals (2018-2022) and Scheme Manager and Technical File Assessor at British Standards Institution (BSI) (2015), a fit for program planning against a regulatory strategy.

    Is this you? Claim your profile and get paid for calls.

  6. Michael Noderer

    LinkedIn

    Experience: Head of Pharma Product Portfolio Combination Products · Bayer

    $740 per 30-minute call

    Michael Noderer has held Head of Pharma Product Portfolio Combination Products at Bayer since July 2020 and Senior Director Drug Delivery Systems there since May 2023. Noderer was Associate Principal Engineer at AstraZeneca (2014-2020), Design Authority at Sanofi (2009-2014) and Design Engineer at Procter & Gamble (2004-2009), holds a Diplom Ingenieur in Mechanical Engineering, and suits questions on managing a combination product portfolio.

    Is this you? Claim your profile and get paid for calls.

  7. Paul Lindstrom MSME, MBA

    LinkedIn

    Experience: Senior Director, R&D, Device and Combination Product Development · AstraZeneca

    $673 per 30-minute call

    Paul Lindstrom MSME, MBA holds two current AstraZeneca titles, Senior Director, R&D, Device and Combination Product Development (since August 2021) and Director in the same group (since 2019), after Director Device Technology, Global Technical Operations (2016-2019). At AbbVie, Lindstrom was CMC Scientific Director, Combination Product Development (2015-2016) and Director Tec Ops, Combination Products (2013-2015), and describes work across development, commercialization and on-market lifecycle management of combination products.

    Is this you? Claim your profile and get paid for calls.

  8. Paul Roussel

    LinkedIn

    Experience: Senior Director-Combination Products · Kiniksa Pharmaceuticals

    $471 per 30-minute call

    Paul Roussel's work centers on device development for combination products, providing engineering leadership in concept development, prototyping, mechanical and biocompatibility evaluation, process and equipment development and production scale-up. Roussel has been Senior Director-Combination Products at Kiniksa Pharmaceuticals since April 2019, held Associate Director, Principal Scientist and Senior Scientist roles at MedImmune, and was Director of Engineering at West Pharmaceutical Services (2004-2009).

    Is this you? Claim your profile and get paid for calls.

  9. Roger Liu

    LinkedIn

    Experience: Director-Combination Product Development · AbbVie

    $539 per 30-minute call

    Roger Liu has been Director-Combination Product Development at AbbVie since July 2017 and names drug product integration, OEM device integration, design controls and BLA, IND, CTA and 510k regulatory work among focus areas. Liu was Director- Delivery Systems Development at MedImmune (2015-2017), Director - Product Development, Self-Injection Business Unit at West Pharmaceutical Services (2013-2015) and Associate Director - Delivery Devices at Biogen (2008-2013).

    Is this you? Claim your profile and get paid for calls.

  10. Shirley Aguirre Baron

    LinkedIn

    Experience: Director of Devices and Combination Products at Alexion · AstraZeneca

    $505 per 30-minute call

    Shirley Aguirre Baron, based in Dublin, has held Director of Devices and Combination Products at Alexion, an AstraZeneca role, since April 2025, after Director, Injectables Portfolio Lead at Viatris (2023-2025) and Global Lead of Combination Products at Chugai, a Roche role (2020-2023). At Owen Mumford, Aguirre Baron was Head of Programmes - Global Operations (2019-2020) and Engineering Project Manager - Combination Products (2016-2019), useful for portfolio and technology transfer questions.

    Is this you? Claim your profile and get paid for calls.

Choose the right perspective

For pen injector and injectables portfolios, Chris Smith (pen-injector combination projects at Teva) and Shirley Aguirre Baron (Injectables Portfolio Lead at Viatris) are the closest fit, and Julie Ann Jones adds respiratory products. Chris Mitchener and Paul Lindstrom hold function-level titles at Eli Lilly and Company and AstraZeneca, while Joyce Y Zhao is the one who names risk management systems and regulatory submissions to FDA, EMA and PMDA.

Questions to take into the conversation

  1. 01How do you decide whether to use an off-the-shelf delivery device or develop a custom one for a new drug?
  2. 02Which design controls and risk management records does the device side need ready before a combination product submission, and who owns them?
  3. 03What tends to cause delays when moving a combination product from clinical supply into commercial launch?

About this directory

This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.

Other perspectives in Pharmaceuticals